Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial (Q44424665)

2 December 2017

Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial (English)

1 reference

2 December 2017

0 references

Z Punthakee

1

1 reference

2 December 2017

J Bosch

2

1 reference

2 December 2017

G Dagenais

3

1 reference

2 December 2017

R Diaz

4

1 reference

2 December 2017

R Holman

5

1 reference

2 December 2017

J L Probstfield

6

1 reference

2 December 2017

A Ramachandran

7

1 reference

2 December 2017

M C Riddle

8

1 reference

2 December 2017

L E Rydén

9

1 reference

2 December 2017

B Zinman

10

1 reference

2 December 2017

R Afzal

11

1 reference

2 December 2017

S Yusuf

12

1 reference

2 December 2017

H C Gerstein

13

1 reference

2 December 2017

TIDE Trial Investigators

14

1 reference

2 December 2017

language of work or name

1 reference

29 October 2011

1 reference

2 December 2017

1 reference

2 December 2017

55

1 reference

2 December 2017

36-45

1 reference

2 December 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s00125-011-2357-4

2 December 2017

0 references

cites work

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Pioglitazone for diabetes prevention in impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

A meta-analysis of the effect of thiazolidinediones on blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

A randomized trial of therapies for type 2 diabetes and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

The PROactive study: some answers, many questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Vitamin D: extraskeletal health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Vitamin D deficiency and risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Calcium/vitamin D supplementation and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Calcium plus vitamin D supplementation and the risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Calcium plus vitamin D supplementation and the risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

The IFCC Reference Measurement System for HbA1c: a 6-year progress report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Clinical outcomes trials and the cardiovascular effects of thiazolidinediones: implications for the evaluation of antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

beta-Blocker therapy in heart failure: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2357-4

Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial

21 January 2018

1 reference

12 December 2020

Why do we need some large, simple randomized trials?

1 reference

12 December 2020

Pioglitazone for type 2 diabetes mellitus

1 reference

12 December 2020

Rosiglitazone for type 2 diabetes mellitus

1 reference

12 December 2020

Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis

1 reference

12 December 2020

10.1007/S00125-011-2357-4

Identifiers

DOI

1 reference

2 December 2017

1 reference